# Nuoning Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuoning-biology

- Industry: Biotechnology
- Headquarters: Beijing, China
- Total disclosed funding: $7.2M
- Latest round: Series A (Oct 31, 2018)
- Investors on record: 2

## About

Based in Beijing, China and established in 2015, Biology is a biotechnology company that focuses on research and developing polymer antibody-drug conjugate (ADC). In 2021, the company raised RMB 35 million in strategic investment from Huadong Medicine Co.,Ltd. The company engages in research and development of polymer antibody-drug conjugate. Nuoning Biology focuses on the research and development of antibody-drug conjugates (ADCs), master's the world's only polymer conjugation technology and third-generation ADC technology and develops multiple ADC products based on core technologies with independent intellectual property rights. The company's products are suitable for diseases such as lung cancer, breast cancer, cervical cancer, ovarian cancer, and prostate cancer, etc. The company’s revenue is generated by selling polymer antibody-drug conjugate to customers. In the future, the company will develop ADC products for different cancers.

## Funding rounds

- Series A, Oct 31, 2018, $7.2M — China Merchants Capital, Junyue Venture

## Investors

- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series A
- Junyue Venture — Series A